^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Xpovio (selinexor)

    i
    Company:
    Antengene, FORUS Therap, Jiangsu Hansoh Pharma, Karyopharm, Menarini, NeoPharm
    Drug class:
    XPO1 inhibitor
    Related drugs:
    Apply
    Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma (NCI-2020-09704) (NCT04640779)
    Phase 1
    Mayo Clinic
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    02/08/2021
    Primary completion :
    08/15/2026
    Completion :
    08/15/2027
    XPO1
    |
    Xpovio (selinexor)
    A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG) (NCT05099003)
    Phase 1/2
    National Cancer Institute (NCI)
    Suspended
    Last update posted :
    02/18/2025
    Initiation :
    05/31/2022
    Primary completion :
    06/30/2027
    Completion :
    06/30/2027
    BRAF • IDH1
    |
    BRAF mutation • BRAF V600 • IDH1 mutation
    |
    Xpovio (selinexor)
    Myeloma-Developing Regimens Using Genomics (MyDRUG) (NCT03732703)
    Phase 1/2
    Multiple Myeloma Research Consortium
    Completed
    Last update posted :
    02/14/2025
    Initiation :
    04/01/2019
    Primary completion :
    12/31/2024
    Completion :
    12/31/2024
    BRAF • SLC1A5
    |
    Venclexta (venetoclax) • Cotellic (cobimetinib) • Verzenio (abemaciclib) • Balversa (erdafitinib) • Xpovio (selinexor) • Ninlaro (ixazomib) • Darzalex (daratumumab) • dexamethasone • Idhifa (enasidenib) • pomalidomide • Blenrep (belantamab mafodotin-blmf) • GDC-0623
    Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (NCI-MATCH) (NCT02465060)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    08/17/2015
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    MSI • CD4
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bicalutamide • leucovorin calcium • bendamustine • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • GSK2636771 • Zirabev (bevacizumab-bvzr) • defactinib (VS-6063) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Provenge (sipuleucel-T) • TQB2440 (pertuzumab biosimilar) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • BCD-178 (pertuzumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)
    Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment (NCT05432804)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/06/2025
    Initiation :
    03/20/2023
    Primary completion :
    06/30/2026
    Completion :
    06/30/2026
    MGMT
    |
    IDH wild-type
    |
    temozolomide • Xpovio (selinexor)
    A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors (NCT05985161)
    Phase 2
    Memorial Sloan Kettering Cancer Center
    Recruiting
    Last update posted :
    02/06/2025
    Initiation :
    08/01/2023
    Primary completion :
    08/01/2029
    Completion :
    08/01/2029
    XPO1
    |
    XPO1 E571K • XPO1 mutation
    |
    Xpovio (selinexor)
    Study of Selinexor in Combination with Ruxolitinib in Myelofibrosis (SENTRY) (NCT04562389)
    Phase 3
    Karyopharm Therapeutics Inc
    Recruiting
    Last update posted :
    02/05/2025
    Initiation :
    03/11/2021
    Primary completion :
    09/01/2025
    Completion :
    03/01/2028
    CD4
    |
    Jakafi (ruxolitinib) • Xpovio (selinexor)
    A Study of Selinexor in Combination With Temozolomide and Anti-PD-1 Antibody in Patients With Relapsed/Refractory Primary Central Nervous System Lymphoma (NCT06556199)
    Phase 1/2
    Second Affiliated Hospital, School of Medicine,...
    Recruiting
    Last update posted :
    08/15/2024
    Initiation :
    08/31/2024
    Primary completion :
    08/31/2026
    Completion :
    08/31/2028
    IFNG • IL6 • TNFA • IL2 • IL10
    |
    temozolomide • Xpovio (selinexor)
    Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial) (NCT06517511)
    Phase 2
    Sun Yat-sen University
    Recruiting
    Last update posted :
    07/24/2024
    Initiation :
    07/11/2024
    Primary completion :
    01/01/2026
    Completion :
    04/01/2028
    TET2 • PTPN2 • DDX3X
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Xpovio (selinexor)
    Selinexor in Combination With MTX+Ritu to Treat R/R CNSL (NCT05698147)
    Phase 1/2
    Tong Chen, MD
    Recruiting
    Last update posted :
    06/17/2024
    Initiation :
    08/03/2023
    Primary completion :
    06/30/2026
    Completion :
    12/31/2026
    IL6 • CXCL13 • IL10
    |
    Rituxan (rituximab) • Xpovio (selinexor)
    Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma (NCT02436707)
    Phase 2
    Canadian Cancer Trials Group
    Recruiting
    Last update posted :
    06/12/2024
    Initiation :
    10/27/2015
    Primary completion :
    12/31/2025
    Completion :
    12/31/2026
    CD20
    |
    cisplatin • Imbruvica (ibrutinib) • gemcitabine • Rituxan (rituximab) • cyclophosphamide • etoposide IV • Xpovio (selinexor) • dexamethasone • mesna • cyclophosphamide intravenous
    Testing Atezolizumab With or Without Selinexor in Patients >= 18 Years Old With Alveolar Soft Part Sarcoma, the Axiom Study (NCT05333458)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    06/05/2024
    Initiation :
    08/29/2022
    Primary completion :
    05/01/2025
    Completion :
    05/01/2025
    PD-L1
    |
    Tecentriq (atezolizumab) • Xpovio (selinexor)
    Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma (XPORT-EC-042) (NCT05611931)
    Phase 3
    Karyopharm Therapeutics Inc
    Recruiting
    Last update posted :
    06/05/2024
    Initiation :
    04/18/2023
    Primary completion :
    01/31/2025
    Completion :
    01/31/2028
    TP53
    |
    TP53 wild-type
    |
    Xpovio (selinexor)
    A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (NCT04442022)
    Phase 2/3
    Karyopharm Therapeutics Inc
    Recruiting
    Last update posted :
    06/05/2024
    Initiation :
    09/03/2020
    Primary completion :
    12/01/2024
    Completion :
    12/01/2025
    MYC • BCL2 • BCL6
    |
    BCL6 rearrangement • BCL2 rearrangement
    |
    cisplatin • gemcitabine • Rituxan (rituximab) • Xpovio (selinexor) • dexamethasone
    Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START) (NCT05035745)
    Phase 1/2
    National University Hospital, Singapore
    Recruiting
    Last update posted :
    05/17/2024
    Initiation :
    03/01/2021
    Primary completion :
    11/01/2024
    Completion :
    11/01/2025
    BRCA
    |
    Talzenna (talazoparib) • Xpovio (selinexor)
    Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma (SINE) (NCT02199665)
    Phase 1
    University of Chicago
    Recruiting
    Last update posted :
    05/14/2024
    Initiation :
    06/12/2014
    Primary completion :
    07/01/2024
    Completion :
    12/25/2024
    CRBN
    |
    Xpovio (selinexor) • carfilzomib • dexamethasone • dexamethasone injection
    Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment (SPRINT) (NCT04256707)
    Phase 1/2
    Karyopharm Therapeutics Inc
    Recruiting
    Last update posted :
    05/07/2024
    Initiation :
    01/14/2020
    Primary completion :
    03/01/2025
    Completion :
    03/01/2025
    KRAS
    |
    KRAS mutation • KRAS wild-type • RAS mutation • RAS wild-type
    |
    Keytruda (pembrolizumab) • docetaxel • 5-fluorouracil • irinotecan • Xpovio (selinexor) • leucovorin calcium
    A Study of VRd-based Regimen Combined With CART-ASCT-CART2 Treatment in NDMM Patients With P53 Abnormalities (NCT05850286)
    Phase 2
    Institute of Hematology & Blood Diseases Hospit...
    Recruiting
    Last update posted :
    02/20/2024
    Initiation :
    04/20/2023
    Primary completion :
    04/01/2025
    Completion :
    04/01/2027
    TP53 • SDC1
    |
    TP53 mutation
    |
    bortezomib • Xpovio (selinexor)
    Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas (NCT02323880)
    Phase 1
    Children's Oncology Group
    Active, not recruiting
    Last update posted :
    01/01/2024
    Initiation :
    10/30/2015
    Primary completion :
    09/30/2022
    Completion :
    09/22/2024
    AFP
    |
    Xpovio (selinexor)
    Selinexor in Combination With R-CHOP Followed by Selinexor Maintenance for Untreated EBV-positive DLBCL Patients (NCT05577364)
    Phase 1/2
    Sun Yat-sen University
    Recruiting
    Last update posted :
    12/14/2023
    Initiation :
    11/01/2022
    Primary completion :
    12/31/2024
    Completion :
    02/28/2026
    PD-L1 • PD-1 • TET2 • LAG3 • CTLA4 • PTPN2 • DDX3X
    |
    TET2 mutation • PTPN2 mutation
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Xpovio (selinexor) • vincristine • prednisone
    Selinexor Combined With R-GDP Regimen for TP53-altered R/R DLBCL (NCT06062641)
    Phase 2
    Ruijin Hospital
    Not yet recruiting
    Last update posted :
    11/07/2023
    Initiation :
    10/30/2023
    Primary completion :
    04/30/2024
    Completion :
    09/30/2027
    TP53
    |
    TP53 mutation • TP53 deletion
    |
    cisplatin • Xpovio (selinexor) • dexamethasone injection
    COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial; (C-SMART) (NCT04534725)
    Phase 3
    Peter MacCallum Cancer Centre, Australia
    Completed
    Last update posted :
    08/24/2023
    Initiation :
    12/17/2020
    Primary completion :
    11/28/2022
    Completion :
    04/19/2023
    CRP
    |
    Xpovio (selinexor) • LENZ (lenzilumab)
    XPO-1 in Combination With RCHOP for DH/TH Lymphoma (NCT05974085)
    Phase 2
    Zhejiang Cancer Hospital
    Recruiting
    Last update posted :
    08/03/2023
    Initiation :
    08/01/2022
    Primary completion :
    12/31/2023
    Completion :
    03/01/2024
    BCL2 • BCL6
    |
    BCL6 rearrangement
    |
    Rituxan (rituximab) • cyclophosphamide • Xpovio (selinexor)
    Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma (NCT04856189)
    Phase 1/2
    Mamta Parikh
    Recruiting
    Last update posted :
    07/03/2023
    Initiation :
    04/08/2021
    Primary completion :
    05/01/2024
    Completion :
    05/01/2024
    PD-L1 • CD4
    |
    Keytruda (pembrolizumab) • cisplatin • Xpovio (selinexor)
    Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery (NCT02120222)
    Phase 1
    Kari Kendra
    Completed
    Last update posted :
    04/04/2023
    Initiation :
    08/22/2014
    Primary completion :
    04/08/2018
    Completion :
    04/08/2018
    BRAF • IL2
    |
    BRAF V600E • BRAF V600 • BRAF V600K
    |
    Xpovio (selinexor)
    Selinexor Combined With R-GemOx as Second-line Treatment in Patients With Diffuse Large B-cell Lymphoma (NCT05786989)
    Phase 4
    Chongqing University Cancer Hospital
    Recruiting
    Last update posted :
    03/28/2023
    Initiation :
    02/28/2023
    Primary completion :
    03/31/2024
    Completion :
    09/30/2024
    CD20
    |
    CD20 positive
    |
    Xpovio (selinexor)
    Selinexor as Single Agent and With Imatinib in Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (SeliGIST) (NCT04138381)
    Phase 1/2
    Grupo Espanol de Investigacion en Sarcomas
    Active, not recruiting
    Last update posted :
    03/27/2023
    Initiation :
    08/16/2019
    Primary completion :
    04/16/2023
    Completion :
    04/16/2023
    KIT • PDGFRA
    |
    PDGFRA mutation
    |
    imatinib • Xpovio (selinexor)
    Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma (NCT05422027)
    Phase 1/2
    Xia Zhongjun
    Recruiting
    Last update posted :
    02/27/2023
    Initiation :
    07/25/2022
    Primary completion :
    06/30/2025
    Completion :
    12/31/2025
    TP53
    |
    TP53 mutation • Chr t(4;14) • Chr t(14;16)
    |
    lenalidomide • bortezomib • Xpovio (selinexor)
    A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma (NCT05028348)
    Phase 3
    European Myeloma Network
    Recruiting
    Last update posted :
    02/22/2023
    Initiation :
    04/19/2022
    Primary completion :
    03/01/2026
    Completion :
    03/01/2029
    CD4
    |
    Xpovio (selinexor) • dexamethasone • pomalidomide • Empliciti (elotuzumab)
    Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies (NCT02025985)
    Phase 2
    Karyopharm Therapeutics Inc
    Completed
    Last update posted :
    01/26/2023
    Initiation :
    04/09/2014
    Primary completion :
    01/24/2017
    Completion :
    03/29/2017
    MUC16
    |
    HR positive • HER-2 negative
    |
    Xpovio (selinexor)
    Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer (NCT01607905)
    Phase 1
    Karyopharm Therapeutics Inc
    Completed
    Last update posted :
    01/26/2023
    Initiation :
    06/18/2012
    Primary completion :
    03/15/2016
    Completion :
    03/15/2016
    EGFR • KRAS
    |
    KRAS wild-type • RAS wild-type
    |
    Xpovio (selinexor)
    Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL) (NCT04607772)
    Phase 1/2
    Karyopharm Therapeutics Inc
    Suspended
    Last update posted :
    01/25/2023
    Initiation :
    11/18/2020
    Primary completion :
    12/01/2025
    Completion :
    12/01/2025
    CD4
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib) • gemcitabine • Rituxan (rituximab) • lenalidomide • oxaliplatin • Xpovio (selinexor) • bendamustine • Monjuvi (tafasitamab-cxix) • Polivy (polatuzumab vedotin-piiq)
    SPEL as Introductive Treatment Following Immune-chemotherapy as Consolidated Therapy for R/R DLBCL With p53 and/or c-Myc Expression (NCT05498636)
    Phase 1/2
    The Affiliated Hospital of Qingdao University
    Not yet recruiting
    Last update posted :
    08/19/2022
    Initiation :
    10/01/2022
    Primary completion :
    07/30/2025
    Completion :
    12/31/2025
    MYC • BCL2
    |
    MYC overexpression • MYC expression • MYC rearrangement • BCL2 rearrangement
    |
    lenalidomide • etoposide IV • Xpovio (selinexor) • prednisone
    A Study of a Fully Human BCMA-targeting CAR (CT103A) Combined With Selinexor in Patients With Relapsed/Refractory Extramedullary Multiple Myeloma (NCT05201118)
    Phase 1
    Chunrui Li
    Recruiting
    Last update posted :
    05/24/2022
    Initiation :
    01/01/2022
    Primary completion :
    12/31/2022
    Completion :
    12/31/2023
    IL6
    |
    Xpovio (selinexor) • Fucaso (equecabtagene autoleucel)
    A Phase I Dose Escalation Study of Selinexor Plus Nivolumab and Ipilimumab in Advanced/Metastatic Solid Malignancies (NEXUS) (NCT04850755)
    Phase 1
    National University Hospital, Singapore
    Recruiting
    Last update posted :
    04/20/2021
    Initiation :
    03/08/2021
    Primary completion :
    11/01/2023
    Completion :
    11/01/2024
    PD-L1
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Xpovio (selinexor)
    Phase 2 Trial of Selinexor (KPT-330) for Metastatic Triple Negative Breast Cancer (TNBC) (NCT02402764)
    Phase 2
    H. Lee Moffitt Cancer Center and Research Insti...
    Completed
    Last update posted :
    09/11/2020
    Initiation :
    07/08/2015
    Primary completion :
    03/10/2016
    Completion :
    06/06/2019
    HER-2 • PGR
    |
    HER-2 negative
    |
    Xpovio (selinexor)
    Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia (NCT02530476)
    Phase 1/2
    M.D. Anderson Cancer Center
    Completed
    Last update posted :
    03/31/2020
    Initiation :
    12/08/2015
    Primary completion :
    04/08/2019
    Completion :
    04/08/2019
    FLT3
    |
    FLT3-ITD mutation • FLT3 D835
    |
    sorafenib • Xpovio (selinexor)
    Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT02093403)
    Phase 1
    Bhavana Bhatnagar
    Completed
    Last update posted :
    12/08/2017
    Initiation :
    03/01/2014
    Primary completion :
    11/26/2016
    Completion :
    11/26/2016
    XPO1
    |
    Xpovio (selinexor) • decitabine